Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study is conducted to evaluate the feasibility and efficacy of post-transplantation
cyclophosphamide with myeloablative or reduced-intensity conditioning regimen for allogeneic
hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS).